Edwards Lifesciences Raises FY25 Outlook
Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better than expected revenues in the third quarter.
Edwards' Q3 2025 revenues grew to $1.55bn, reflecting an uplift of 14.7% from around $1.35bn in Q3 2024. The company achieved sales growth of 14.7% to around $1.55bn in Q3.
- Q3 revenues: $1.55bn
- Q3 sales growth: 14.7%
- FY25 sales growth expectation: high end of 9% to 10%
- FY25 share price guidance: $2.56 to $2.62
The company's Q3 revenues were chiefly driven by a 12.4% uplift in its transcatheter aortic valve replacement (TAVR) product group.
The gold standard of business intelligence.
Author's summary: Edwards Lifesciences raises FY25 outlook after strong Q3 results.
More News
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- IndiGo Flights Cancellation Live Updates
- Vilnius Airport grounds flights after suspected Belarusian balloons detected
- GRIDLOCK Definition & Meaning
- Women’s Big Bash League 2025-26 results
- Benin Rejects Claims of a Coup by Opposition Soldiers
- Tartan Army set for ‘big bash’ in Boston with two games in New England
- PREDICTED TEAM: How Scorchers will line up for BBL opener
- Benin authorities say coup attempt foiled, President Talon safe
- Congress gridlocked on key issues as year-end deadline looms